Corpus ID: 90285739

interferon-free Treatment with Faldaprevir, Deleobuvir (bi 207127) and Ribavirin in Sound-c3: 95% Svr12 in Hcv-gt1b : 1102

  title={interferon-free Treatment with Faldaprevir, Deleobuvir (bi 207127) and Ribavirin in Sound-c3: 95\% Svr12 in Hcv-gt1b : 1102},
  author={Jean-François Dufour and Mar{\'i}a Buti and Vincent Soriano and Robert J. Buynak and Parvez Mantry and Jawahar Taunk and Jerry O. Stern and Richard Vinisko and J. Gallivan and W. O. Boecher and Federico J Mensa and Stefan Zeuzem},

Topics from this paper

Advances in and the future of treatments for hepatitis C
The authors are now at the beginning of an era where combinations of direct-acting antiviral agents may pave the way for interferon-free regimens, even improving the viral clearance rate to near 100%. Expand
Frontiers in the treatment of hepatitis C virus infection.
There has been an explosion of reports on medications from different classes, promising a dramatic expansion to an all-oral regimen for the treatment of HCV genotype 1 infection within the next few years. Expand
Interferon-free regimens in the liver-transplant setting.
There are some issues that need to be addressed in the peri-LT setting of IFN-free regimens in patients with advanced cirrhosis and portal hypertension, pharmacokinetics of new antivirals in Patients with several grades of hepatic or renal impairment, and drug-drug interactions. Expand
New hepatitis C therapies: the toolbox, strategies, and challenges.
This review describes the different classes of drugs and their mechanisms and properties, as well as treatment strategies in development, including those that are interferon-based and interferons-free. Expand
Perspectivas futuras del tratamiento de la hepatitis C, ¿sin interferón y sin ribavirina?
Las combinaciones libres de interferon (y ribavirina) se presentan como tratamientos de primera linea muy seguros y bien tolerados, aunque es posible that el coste of estas terapias sea elevado. Expand
Safety of direct-acting antivirals in the treatment of chronic hepatitis C
This review addresses the early identification and management of AEs to improve tolerance, and to avoid reduction in SVR rates with the next generation of antivirals. Expand
The role of interferon in the new era of hepatitis C treatments
The role Interferon will play in the next era of HCV treatment will depend upon balancing cost, efficacy and the development of an interferon with a more favorable adverse event profile. Expand
Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation.
In the transplant setting it is also relevant to learn which strategy is most cost-effective in minimizing the negative impact of hepatitis C: preventing graft infection by treating patients before transplantation or treating hepatitis C recurrence after LT. Expand
Interferon-Free Regimens for Hepatitis C: Combine and Conquer
This paper reviews the interferon-free regimens currently in phase II or III for which sustained virologic response data are available and discusses the successes and potential pitfalls of these regimens. Expand